CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 39 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-07-27 | Trucksis Michele Chief Medical Officer and EVP | Exercise or conversion | +38,064 | $15.77 | $600K | 38,064 |
| 2016-07-27 | Trucksis Michele Chief Medical Officer and EVP | Sale | −38,064 | $35.14 | $1.3M | 0 |
| 2016-07-27 | Trucksis Michele Chief Medical Officer and EVP | Exercise or conversion · Stock Option (Right to Buy) | +38,064 | 301,060 | ||
| 2016-07-25 | Aunins John G. Chief Technology Officer & EVP | Sale | −9,390 | $34.18 | $321K | 210,765 |
| 2016-07-22 | Aunins John G. Chief Technology Officer & EVP | Exercise or conversion | +187,500 | $0.48 | $90K | 220,155 |
| 2016-07-22 | Aunins John G. Chief Technology Officer & EVP | Exercise or conversion · Stock Option (right to buy) | −187,500 | 12,500 | ||
| 2016-07-06 | Pomerantz Roger President and CEO | Exercise or conversion | +35,435 | $0.71 | $25K | 219,127 |
| 2016-07-06 | Pomerantz Roger President and CEO | Sale | −9,900 | $29.27 | $290K | 209,227 |
| 2016-07-06 | Pomerantz Roger President and CEO | Sale | −25,535 | $29.80 | $761K | 183,692 |
| 2016-07-06 | Pomerantz Roger President and CEO | Exercise or conversion · Stock Option (right to buy) | −35,435 | 1,072,283 | ||
| 2016-07-05 | Pomerantz Roger President and CEO | Exercise or conversion | +52,776 | $0.71 | $37K | 236,468 |
| 2016-07-05 | Pomerantz Roger President and CEO | Sale | −49,871 | $29.27 | $1.5M | 186,597 |
| 2016-07-05 | Pomerantz Roger President and CEO | Sale | −2,905 | $29.96 | $87K | 183,692 |
| 2016-07-05 | Pomerantz Roger President and CEO | Exercise or conversion · Stock Option (right to buy) | −52,776 | 1,107,718 | ||
| 2016-07-01 | Pomerantz Roger President and CEO | Exercise or conversion | +56,789 | $0.71 | $40K | 240,481 |
| 2016-07-01 | Pomerantz Roger President and CEO | Sale | −4,832 | $29.12 | $141K | 235,649 |
| 2016-07-01 | Pomerantz Roger President and CEO | Sale | −41,957 | $29.84 | $1.3M | 193,692 |
| 2016-07-01 | Pomerantz Roger President and CEO | Sale | −10,000 | $30.00 | $300K | 183,692 |
| 2016-07-01 | Pomerantz Roger President and CEO | Exercise or conversion · Stock Option (right to buy) | −56,789 | 1,160,497 | ||
| 2016-06-30 | Shaff Eric D. CFO and EVP | Exercise or conversion | +4,533 | $7.79 | $35K | 4,533 |
Page 32 of 34 · 662 trades